Abstract
Chimeric antigen receptors (CARs) are artificial recombinant receptors that generally combine the antigen-recognition domain of a monoclonal antibody with T cell activation domains. Recent years have seen great success in clinical trials employing CD19-specific CAR-T cell therapy for B cell leukemia. Nevertheless, solid tumors remain a major challenge for CAR-T cell therapy. This review summarizes the preclinical and clinical studies on the treatment of solid tumors with CAR-T cells. The major hurdles for the success of CAR-T and the novel strategies to address these hurdles have also been described and discussed.
Keywords:
T cell; adoptive cell therapy; chimeric antigen receptor; solid tumor.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Clinical Trials as Topic / methods
-
Forecasting
-
Genetic Engineering / methods
-
Humans
-
Immunotherapy, Adoptive / methods*
-
Immunotherapy, Adoptive / trends
-
Neoplasms / genetics
-
Neoplasms / immunology
-
Neoplasms / therapy*
-
Outcome Assessment, Health Care / methods
-
Outcome Assessment, Health Care / trends
-
Receptors, Antigen, T-Cell / genetics
-
Receptors, Antigen, T-Cell / immunology*
-
Receptors, Antigen, T-Cell / metabolism
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / immunology*
-
Recombinant Fusion Proteins / metabolism
-
T-Lymphocytes / immunology
-
T-Lymphocytes / metabolism
-
T-Lymphocytes / transplantation*
Substances
-
Receptors, Antigen, T-Cell
-
Recombinant Fusion Proteins